Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Tivozanib vs Sorafenib in RCC
NCT01076010Phase 3Completed
- Sponsor
- AVEO Oncology
- Start
- Mar 2010
- Primary completion
- Jul 2014
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 15
01
Overview
A Phase 3 trial of tivozanib in renal cell carcinoma (RCC), sponsored by AVEO Oncology. Started Mar 2010; status: completed.
02
Drugs
tivozanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01076010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01076010.